PDGFRA and systemic sclerosis: In general, the data presented here provide evidence that PDGFR-α siRNA is an effective gene therapeutic method against fibrosis, reduces PDGFR-α mRNA and protein expression, and inhibits the activation and transdifferentiation of fibroblasts in SSc skin lesions.